This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
How can PDOs revolutionise drug discovery and deepen our understanding of disease? Patient-derived organoids (PDOs) are proliferative 3D cell structures derived from tissue samples of both healthy and diseased tissue. What sets PDOs apart from traditional 2D cell and animal models used in drug discovery?
Dr. Zeldis, who formerly served as Chief Medical Officer (CMO) and Head of Clinical Research, Medical Affairs, and Drug Safety, at Celgene, and CEO of Celgene Global Health, helped guide Celgene’s expansion into one of the biotechnology industry’s most successful companies. .
GAITHERSBURG, Md.,
By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cellbiology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.
Cardiovascular diseases are the leading cause of mortality worldwide, and traditional approaches like drug therapy or invasive procedures manage symptoms but do not restore lost cardiac tissue. While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies.
“Antibody responses are not likely to be the sole determinant of someone’s outcome,” said Scott Boyd, associate professor of pathology at Stanford. Some of these patients mount a vigorous immuneresponse, and others have a more moderate response. There are also other branches of the immune system involved.
In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immuneresponses similar to a traditional injection. Printed vaccines caused mice to have a faster immuneresponse. Nature CellBiology. But the printed vaccines are very good! Cecilia Manduca on Medium.
In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immuneresponses similar to a traditional injection. Printed vaccines caused mice to have a faster immuneresponse. Nature CellBiology. But the printed vaccines are very good! Cecilia Manduca on Medium.
Sponge cells double in population quite quickly — around 40 minutes — and could be engineered to manufacture drugs. Read Hematopoietic stem-cell gene therapy is associated with restored white matter microvascular function in cerebral adrenoleukodystrophy. Nature CellBiology. ACS Synthetic Biology.
This looks like an early step toward a much different future for biology: One in which natural language is used to design experiments, program robots, and automate experiments in high-throughput. Skin microbes can trigger strong immuneresponses. epidermidis , can actually trigger tumor-specific T cells. Nature Protocols.
Learnings regarding immune geography and cell:cell contact are increasingly important as we consider how best to advance cell therapies for diverse hematologic malignancies and solid tumors ( www.aletabio.com ). This was an interesting finding and one that I think remains under-appreciated by the immuno-oncology drug development field.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content